Senior Patient Safety Physician-Inflammation

The Position

Lead the Future of Medicine – as Senior Patient Safety Physician– Inflammation

To ensure the fastest and most focused path from strategy to patients, we are evolving our OneHP organization. Together, we are simplifying our structures, strengthening the accountability of Therapeutic Areas, and creating clear interfaces between Innovation and Business. This ensures that our assets are efficiently transformed into successful brands – with the ultimate goal of delivering lasting value to patients around the world. Therefore, we are looking for a patient safety physician to join us in accomplishing this vision. Your mission: elevate early clinical development, accelerate the path to Proof of Concept, and pave the way for breakthrough therapies. As Senior Patient Safety Physician - Inflammation you have the responsibility for the pharmacovigilance risk management activities of investigational compounds on a global level.

Join us in shaping the future of medicine – apply now!

This position can be filled in Ingelheim or Biberach.

Tasks & responsibilities
In your new role, you will design and implement proactive, patient-centric risk management strategies for assigned compounds, ensuring alignment with global safety standards.
Furthermore, leading all pharmacovigilance activities for your designated products, you will be responsible for planning, execution, and continuous oversight up to POC.
To support effective safety monitoring, you will establish and refine safety analyses within clinical trial and safety databases.
Moreover, a key aspect of your work involves continuously evaluating and enhancing the benefit-risk profile of your products by integrating clinical data and patient insights.
You will engage in close collaboration with internal teams and external stakeholders to address safety concerns and implement appropriate risk mitigation strategies.
In addition, your medical-scientific expertise will be essential in preparing regulatory documents such as DSURs, and trial related documents such as investigator’s brochure, clinical trial protocols, clinical reports ensuring accuracy and compliance.
In your senior capacity, you will chair the multidisciplinary Asset Benefit-Risk Team and represent experimental medicine Patient Safety in strategic committees and regulatory interactions.
On top of that, you will contribute to strategic projects within Experimental Medicine such as future software solutions, strategic initiatives and addressing changing global regulatory environment.
Requirements
Medical Doctor with long-standing clinical or research experience in inflammation therapeutic
Profound experience in pharmacovigilance and Risk Management in a pharmaceutical company on a global / corporate level, including in clinical development
Experience in Clinical Development and submissions for marketing authorization would be an asset
Experience with advanced therapies such as TcE and Car-T would be an asset
Thorough understanding of pharmacovigilance regulation in major markets and respective need for compliance as well as sound medical-scientific and clinical knowledge and judgement
Very good and broad understanding of the pharmaceutical industry, and the future trends and developments including pharmacovigilance
Strong leadership skills paired with the ability to lead projects and influence teams and to collaborate across divisions and work in virtual teams
Profound Project Management competencies with excellent interpersonal and communication skills as well as a strong ethical sense combined with quality and patient safety mindset
Excellent English skills, both written and spoken
Ready to contact us?

If you have any questions about the job posting or process - please contact our HR Direct Team, Tel: +49 (0) 6132 77-3330 or via mail: [email protected]

Recruitment process:
Step 1: Online application - The job posting is presumably online until February 6th, 2026. We reserve the right to take the posting offline beforehand. Applications up to January 13th, 2026 are guaranteed to be considered.
Step 2: Virtual meeting in January until beginning of February
Step 3: Panel interviews in February